How Funding Cuts Could Limit Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing, commonly called CPET or an exercise gas analysis, helps clinicians understand how the heart, lungs, circulation and muscles respond to exertion. It can clarify unexplained breathlessness, distinguish cardiac from respiratory limitations, assess exercise capacity and guide decisions about treatment or rehabilitation.

The test usually involves cycling or walking while equipment records oxygen uptake, carbon dioxide production, breathing patterns, heart rhythm, blood pressure and perceived effort. It requires specialised staff, calibrated technology and medical oversight, so its availability depends heavily on how hospitals, clinics and clinicians are funded.

The American debate about Medicare physician fee schedule reductions offers a useful warning for Australian patients and practices. Australia has its own Medicare Benefits Schedule, state-based public hospitals and private billing arrangements, yet financial pressure can produce similar results: fewer testing sessions, longer waits and a narrower range of patients able to access specialist assessment.

What CPET Adds To Clinical Care

A standard treadmill test or spirometry can answer important questions, but neither always explains why a person becomes short of breath. CPET combines respiratory and cardiovascular measurements during controlled exertion. The resulting pattern can help identify heart failure, pulmonary vascular disease, chronic lung disease, deconditioning or a mixture of causes.

The test is also valuable before and after major treatment. A cardiologist may use it when assessing advanced heart failure, while a respiratory physician may order it for persistent dyspnoea that has not been explained by scans or lung function tests. Exercise physiologists and rehabilitation teams can use the results to set safer training limits and measure progress.

For patients, the value is practical rather than abstract. A clear diagnosis can prevent repeated appointments and inconclusive investigations. It may also guide a referral to cardiac rehabilitation, pulmonary rehabilitation or other support. The campaign’s patient resources explain why access to appropriate cardiovascular assessment matters when policy decisions affect clinical services.

Why Payment Pressure Matters

A CPET service carries costs beyond the appointment itself. A laboratory needs a metabolic cart, cycle ergometer or treadmill, electrocardiography equipment, consumables, infection-control procedures and regular maintenance. Staff must be trained to conduct the test, recognise risk and interpret results. A funding reduction can therefore make each session less financially sustainable, especially when appointment time is long.

In the United States, cuts to physician payments can encourage practices to reduce low-margin services, limit staffing or stop offering complex investigations. Australian providers face different rules, but the underlying pressure can be familiar. A public hospital may need to prioritise urgent activity, while a private clinic may increase out-of-pocket fees or reserve appointments for referrals that are more financially viable.

That matters because CPET is rarely a quick, high-volume procedure. A patient may need pre-test screening, medication review, exercise familiarisation and post-test monitoring. If reimbursement does not reflect the work involved, the service can become vulnerable even when clinicians consider it medically valuable.

How Access Could Change In Australia

Australia’s system creates several pathways to CPET. A patient in inner Melbourne or Sydney may be referred through a major teaching hospital, a private cardiology practice or a respiratory clinic. Someone in regional Queensland, Western Australia or Tasmania may have fewer local options and need to travel to a larger centre. Public referral criteria, local equipment and specialist availability can determine the waiting time.

Funding reductions could affect that pathway in gradual ways. Clinics might offer fewer testing days, combine CPET with narrower referral criteria or delay replacement of ageing equipment. Hospitals could concentrate advanced exercise testing in metropolitan facilities. Patients might then face travel, parking, time away from work and accommodation costs before paying any clinical fee.

The difference between bulk-billed, subsidised and privately billed care can also become more important. A person with a concession card may still struggle if the nearest suitable service is several hours away. A private appointment may be available sooner, but a gap payment can be a serious barrier for families already managing medicines, transport and reduced income.

Potential change	Effect on patients	Effect on clinicians and services
Fewer funded testing sessions	Longer waits and delayed diagnosis	Pressure to prioritise the most urgent referrals
Higher out-of-pocket charges	Some patients defer or cancel testing	More time spent explaining costs and alternatives
Reduced regional capacity	Travel to Sydney, Melbourne, Brisbane or another hub	Greater reliance on tertiary centres
Older or unavailable equipment	Fewer reliable appointment slots	Maintenance delays and limited testing capability
Narrower referral criteria	People with complex or unclear symptoms may wait longer	Less opportunity to investigate mixed cardiac and respiratory causes

Who Feels The Effects First

People with unexplained breathlessness are likely to be affected early because their diagnosis may require several stages of investigation. A patient can have relatively normal results at rest while developing a significant abnormality during exertion. If CPET is unavailable, clinicians may need to rely on a sequence of separate tests that takes longer and may still leave uncertainty.

Patients with heart failure, pulmonary hypertension, congenital heart disease or severe lung disease can also depend on specialist exercise assessment. CPET may help estimate functional limitation, support treatment planning or assess whether rehabilitation is appropriate. Interruptions to testing can make it harder to monitor a changing condition.

Access problems are often sharper outside capital cities. In the bush, a local general practitioner may recognise the need for a specialist test but have no nearby laboratory to which they can refer. A visiting specialist service or telehealth consultation may help with advice, but remote review cannot replace the supervised exercise test itself. The result can be a long trip to a tertiary hospital and a delay between referral, testing and follow-up.

Aboriginal and Torres Strait Islander patients, older Australians and people with disability may face additional transport, communication or cultural safety barriers. A funding decision that looks small in a budget can therefore have a larger effect on people who already encounter obstacles in reaching specialist care.

Practical Steps For Protecting Access

Patients and referring clinicians can reduce avoidable delays by making the referral information as complete as possible. The reason for testing, relevant imaging, lung function results, medication list, symptom history and exercise limitations help a service triage appropriately. They also reduce duplicated appointments when the patient reaches a specialist centre.

Useful steps include:

• Ask whether the service is public, bulk-billed, privately billed or subject to a gap payment.
• Confirm whether the referral needs a cardiologist, respiratory physician or general practitioner.
• Request an estimate of the waiting period and ask about cancellation lists.
• Discuss travel assistance or hospital transport options before booking.
• Bring previous test results, medication details and a clear description of exertional symptoms.
• Ask how results will be explained and which clinician will coordinate follow-up.

Patients should not stop prescribed medicines or attempt strenuous exercise to “prepare” for CPET without clinical advice. The laboratory will provide instructions about medication, food, clothing and activity before the appointment. Clear communication is especially important when symptoms include chest pain, fainting, severe breathlessness or palpitations.

Clinicians can also identify whether a local exercise test, lung function assessment or rehabilitation review can safely answer part of the question while CPET is being arranged. That is not a substitute when comprehensive cardiopulmonary data are needed, but it may support care during a waiting period.

Building A Stronger Case For Services

The most persuasive case for maintaining CPET capacity connects funding with outcomes. Services can track referral numbers, waiting times, cancellation rates, travel distances and the proportion of tests that change diagnosis or management. These measures show administrators how a laboratory contributes to patient flow rather than presenting the test as an isolated technical procedure.

Australian hospitals and clinics can also work with cardiologists, respiratory physicians, exercise physiologists, general practitioners and patient groups to describe local demand. A service in Newcastle, Geelong or regional Queensland may have a different population and referral pattern from a city laboratory, so national averages may conceal important gaps.

Professional advocacy has a role when payment schedules or hospital budgets are reviewed. Decision-makers need to understand that a reduction in reimbursement can affect staffing, equipment renewal and geographic coverage. Patients’ accounts are valuable because they show what a delayed or unavailable test means in everyday life: postponed treatment, repeated travel and uncertainty about what the body can safely manage.

Protecting access does not mean every patient must receive CPET. Appropriate triage remains essential, and some people will need a different investigation. The aim is to ensure that when a specialist believes exercise gas analysis is clinically indicated, cost or location does not become the deciding factor.

Funding choices should preserve the capacity to investigate breathlessness accurately and manage cardiovascular and respiratory disease early. Patients, clinicians and health organisations can support that goal by documenting access barriers, sharing credible experiences and engaging with policymakers when service reductions are proposed. Speaking up through professional bodies, local health networks and patient advocacy campaigns helps keep specialised testing visible in decisions about Medicare, hospital budgets and clinical priorities.